SIREN : 825052715
BIO & COMPAGNIE is a French company founded 9 years ago, specialized in the sector Activités des sociétés holding. Based in ROCHEFORT (17300), this company of category PME shows in 2024 a revenue of 150 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 150 000 € | 150 000 € | 126 875 € | 180 000 € | 180 000 € | 180 000 € | 180 000 € | 120 000 € |
| Net income | 7 720 € | 2 088 € | 86 797 € | 81 875 € | 120 348 € | 100 270 € | 26 404 € | -123 € |
| EBITDA | 214 € | 1 679 € | -25 012 € | 11 379 € | 35 218 € | 33 302 € | 34 330 € | 2 657 € |
| Net margin | 5.1% | 1.4% | 68.4% | 45.5% | 66.9% | 55.7% | 14.7% | -0.1% |
In 2024, BIO & COMPAGNIE achieves revenue of 150 k€. Revenue is growing positively over 8 years (CAGR: +3.2%). Slight decline of 0% vs 2023. After deducting consumption (0 €), gross margin stands at 150 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 214 €, representing 0.1% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 8 k€, i.e. 5.1% of revenue. This profit can be retained or distributed to shareholders.
150 000 €
150 000 €
214 €
187 €
7 720 €
0.1%
The debt ratio (= Financial debt / Equity x 100) stands at 11%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 89%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 10.4 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 5.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
11.196%
88.918%
5.147%
10.375
In 2024, the debt ratio of BIO & COMPAGNIE (11.20) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of BIO & COMPAGNIE (88.9%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of BIO & COMPAGNIE (10.38) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 5673.86. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 326.6x. Operating income very largely covers interest expenses: high safety margin.
5673.864
326.636
In 2024, the liquidity ratio of BIO & COMPAGNIE (5673.86) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of BIO & COMPAGNIE (326.6x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 60 days. Excellent situation: suppliers finance 60 days of the operating cycle (retail model). Overall, WCR represents 751 days of revenue, i.e. 313 k€ to permanently finance. Over 2017-2024, WCR increased by +1105%, requiring additional financing.
312 891 €
0 j
60 j
0 j
751 j
Based on 54 transactions of similar company sales
in 2024,
the value of BIO & COMPAGNIE is estimated at
29 266 €
(range 18 008€ - 43 920€).
With an EBITDA of 214€, the sector multiple of 4.8x is applied.
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare BIO & COMPAGNIE with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of BIO & COMPAGNIE in 2024 is 150 k€.
Yes, BIO & COMPAGNIE generated a net profit of 8 k€ in 2024.
The headquarters of BIO & COMPAGNIE is located in ROCHEFORT (17300), in the department Charente-Maritime.
The tax return of BIO & COMPAGNIE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BIO & COMPAGNIE operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.